Market research
LBL.V Lattice Biologics Ltd
V CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -11.68
Profile
Company facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA5184101056
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -11.68
About
About Lattice Biologics Ltd
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops novel amniotic fluid-based products, such as AmnioBoost and AmnioBlast. The company also offers traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, hernia repair, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior and posterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LBL.V discussion.
5 years, 5 months ago
Lattice Biologics Ltd is currently in a long term downtrend where the price is trading 19.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.5.
Lattice Biologics Ltd's total revenue sank by 32.2% to $475K since the same quarter in the previous year.
Its net income has dropped by 285.1% to $-269K since the same quarter in the previous year.
Finally, its free cash flow fell by 748.5% to $-147K since the same quarter in the previous year.
Based on the above factors, Lattice Biologics Ltd gets an overall score of 1/5.